| Control group | GDFT group | P value |
---|---|---|---|
Net amount infused, [ml, median (IQR)] | 2750 (2250–3300) | 1975 (1575–2600) | < 0.001* |
Crystalloid, [ml, median (IQR)] | 2200 (2025–2513) | 1600 (837–2100) | < 0.001* |
Colloid, [ml, median (IQR)] | 500 (0–1000) | 500 (500–1000) | 0.981 |
Urine output, [ml, median (IQR)] | 350 (200–800) | 600 (300–800) | 0.041* |
Blood loss, [ml, median (IQR)] | 100 (0–350) | 100 (50–225) | 0.970 |
Vasopressor or inotrope, n (%) | 18 (36) | 27 (54) | 0.072 |
 Norepinephrine, n[mg, median (IQR)] | 10 [0.04(0.02–0.10)] | 13 [0.06(0.04–0.12)] | |
 Dobutamine, n[mg,median (IQR)] | 2 [2.62(0–3.50)] | 6 [2.55(0–3.50)] | |
 Phenylephrine, n[mg, median (IQR)] | 6 [0.05(0.01–0.1)] | 7 [0.04(0.02–0.05)] | |
 Ephedrine, n[mg,median (IQR)] | 0 | 1 [6] |